Minimal change disease; This literature-non-study case was reported in a literature article and describes the occurrence of GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Concurrent medical conditions included Glomerulonephritis minimal lesion.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) (seriousness criterion medically significant). The patient was treated with RITUXIMAB for Minimal change disease, at an unspecified dose and frequency. At the time of the report, GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood albumin: 2.5g/dl Laboratories during presentation was 2.5 g/dl and 4.4g/dl Laboratories during last follow up was 4.4  g/dl. On an unknown date, Blood creatinine: base line scr 1 mg/dl base line SCr 1 mg/dl, 1.6g/dl Laboratories during presentation was 1.6 g/dl and 1.5g/dl Laboratories during last follow up was 1.5g/dl. On an unknown date, Protein urine: 19g/d Laboratories during presentation was 19 g/d and 0.07g/d Laboratories during last follow up was 0.07 g/d. On an unknown date, Red blood cells urine: lessthan(<)3 /high power field(hpf) Laboratories during presentation was less than (<) 3 /HPF and 0-2/hpf Laboratories during last follow up was 0-2/HPF.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered GLOMERULONEPHRITIS MINIMAL LESION (Minimal change disease) to be possibly related.    Concomitant medications were not reported.  This article reports a case series of patients who developed new or relapsing GN post vaccination.  Patient was presented with symptom of edema. She was also treated with High dose steroid  Duration of remission before relapse was 1 month and Follow up was taken after 02 month.  This literature-non-study case concerns a 67-year-old female patient with relevant medical history of glomerulonephritis minimal lesion who experienced serious unexpected event of glomerulonephritis minimal lesion relapse. The event occurred approximately 3 weeks after the second dose of Spikevax. The patient presented with the symptom of edema and the patient was in remission for one month prior to relapse. The patient received high dose steroid therapy and Rituximab as a corrective treatment for the event with positive response. Rechallenge was not applicable since the event occurred after the second dose so no rechallenge was done and recurrence was not applicable.  The benefit-risk relationship of drug is not affected by this report. Causal or contributing role of Spikevax in triggering relapse of pre-existing condition cannot be excluded based on the information provided.   This case was linked to MOD-2021-357261, MOD-2021-357609, MOD-2021-357610, MOD-2021-357611, MOD-2021-357613, MOD-2021-357614 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Oct-2021: Follow up received by safety 22-Oct-2021 included an Email and does not contain any new information; Sender's Comments: This literature-non-study case concerns a 67-year-old female patient with relevant medical history of glomerulonephritis minimal lesion who experienced serious unexpected event of glomerulonephritis minimal lesion relapse. The event occurred approximately 3 weeks after the second dose of Spikevax. The patient presented with the symptom of edema and the patient was in remission for one month prior to relapse. The patient received high dose steroid therapy and Rituximab as a corrective treatment for the event with positive response. Rechallenge was not applicable since the event occurred after the second dose so no rechallenge was done and recurrence was not applicable.  The benefit-risk relationship of drug is not affected by this report. Causal or contributing role of Spikevax in triggering relapse of pre-existing condition cannot be excluded based on the information provided.